Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | CTH | P32929 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24211892 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| SCHEMBL8011653 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| SCHEMBL8011652 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| SCHEMBL9134788 | 0.81 | KMT2A (0.73) | SMN1; SMN2MEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL9134794 | 0.81 | KMT2A (0.73) | SMN1; SMN2MEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL21162646 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| Nicothiazone SCHEMBL27963917 | 0.80 | CTH (0.67) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| Nicothiazone SCHEMBL2110572 | 0.80 | CTH (0.67) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| SCHEMBL13380947 | 0.78 | CTH (0.57) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| SCHEMBL19449709 | 0.78 | CTH (0.57) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190201414-A1 | INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-07-04 | — | — | US | disclosed |
| US-8450368-B2 | Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450368-B2 | Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2013-05-28 | — | — | US | disclosed |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | HMOX1, HMOX2, PPOX | SMN1; SMN2 4680/4885MEN1 4396/4885KMT2A 3310/4885 |
| US-20190201414-A1 | INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION | HMOX1, HMOX2, PPOX | SMN1; SMN2 4469/4885MEN1 2939/4885KMT2A 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.